NASDAQ
31.10.25 | 20:59
68,85 US-Dollar
-0,12 % -0,08
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Tarsus Pharmaceuticals, Inc: Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | 1 | GlobeNewswire (USA) | ||
| 20.10. | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | 3 | Investing.com | ||
| 07.08. | Tarsus targets 95,000-100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum | 3 | Seeking Alpha | ||
| 06.08. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | 446 | GlobeNewswire (Europe) | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 06.08. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.08. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 18.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.06. | Tarsus Pharmaceuticals auf Goldman Sachs Konferenz: Fokus auf strategisches Wachstum | 3 | Investing.com Deutsch | ||
| 02.06. | Oppenheimer assumes Tarsus stock at outperform on strong sales | 1 | Investing.com | ||
| 27.05. | Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 2 | Benzinga.com | ||
| 27.05. | H.C. Wainwright sets $72 target for Tarsus stock with Buy rating | 2 | Investing.com | ||
| 01.05. | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | 797 | GlobeNewswire (Europe) | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| 13.01. | Tarsus Pharmaceuticals, Inc: Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care | 671 | GlobeNewswire (Europe) | Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for... ► Artikel lesen | |
| 13.11.24 | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements | 284 | GlobeNewswire (Europe) | Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining... ► Artikel lesen | |
| 05.11.24 | Tarsus Pharmaceuticals, Inc: Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer | 168 | GlobeNewswire (Europe) | IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| MODERNA | 23,620 | -1,11 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,185 | +0,51 % | Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences | ||
| KUROS BIOSCIENCES | 32,300 | -0,31 % | Kuros erhöht nach den ersten neun Monaten das Umsatzziel | Schlieren - Das Medtechunternehmen Kuros zeigt sich nach den ersten neun Monaten zuversichtlicher betreffend der Umsatzentwicklung im Gesamtjahr 2025. Von Januar bis September erhöhte das Unternehmen... ► Artikel lesen | |
| ABIVAX | 90,20 | +0,67 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| RELIEF THERAPEUTICS | 3,370 | 0,00 % | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
29-Oct-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,675 | -1,66 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| DENALI THERAPEUTICS | 13,920 | -1,45 % | Denali Therapeutics Inc.: Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) | SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,110 | +0,26 % | CytomX Therapeutics Inc.: CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| ROCKET PHARMACEUTICALS | 3,296 | +0,61 % | FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock | ||
| SYNDAX PHARMACEUTICALS | 12,100 | +0,83 % | Syndax Pharmaceuticals Q3 2025 Earnings Preview | ||
| ASCENDIS PHARMA | 178,00 | +1,71 % | Ascendis Pharma: New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality ... | COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with... ► Artikel lesen | |
| JASPER THERAPEUTICS | 2,320 | +7,16 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants | REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a clinical-stage biotechnology company focused on development of briquilimab, a novel... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 3,090 | +1,98 % | XFRA 2QV: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCHEMOMAB THER. ADR/20... ► Artikel lesen |
TARSUS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 68,85 Euro und damit -0,12 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.